旨在评估2018年FIGO宫颈癌分期系统中IIIC期与IIIA和IIIB期之间生存结果的差异。在PubMed、EMBASE、MEDLINE和Web of Science上检索了2018年11月1日至2023年1月31日发表的文章。考虑以英文发表的文章。纳入的研究比较了FIGO 2018 IIIC期宫颈癌患者与IIIA和IIIB期宫颈癌患者的生存结果。针对罕见组织病理学类型的研究被排除在外。使用Stata 17软件进行统计分析。终点为总生存期（OS）和无进展生存期（PFS）。 10 项回顾性队列研究符合资格，涉及 2113 名（6.2%）、9812 名（28.6%）、44 名（0.1%）、10 171 名（29.7%）、 11 677 (34.1%) 和 445 (1.3%) 患者处于 IIIA、IIIB、IIIA 期

To assess the difference in survival outcomes between stage IIIC and stages IIIA and IIIB in the 2018 FIGO cervical cancer staging system.The PubMed, EMBASE, MEDLINE and Web of Science were searched for articles published from November 1, 2018 to January 31, 2023. Articles published in English were considered. The included studies compared the survival outcomes of patients with cervical cancer in FIGO 2018 stage IIIC with those in stages IIIA and IIIB. Studies focused on rare histopathological types were excluded. The statistical analyses were performed using Stata 17 software. The endpoints were overall survival (OS) and progression-free survival (PFS).Ten retrospective cohort studies were eligible, involving 2113 (6.2%), 9812 (28.6%), 44 (0.1%), 10 171 (29.7%), 11 677 (34.1%) and 445 (1.3%) patients in stage IIIA, IIIB, IIIA&B, IIIC, IIIC1, and IIIC2, respectively. In the OS group, stage IIIC/C1 was significantly associated with superior survival compared with stage IIIA (hazard risk [HR] 0.62, 95% confidence interval [CI] 0.41-0.93, P = 0.022; I2  = 92.9%) and stage IIIB(A&B) (HR 0.56, 95% CI 0.44-0.71, P < 0.001; I2  = 94.0%). The FIGO 2018 stage IIIC2 was not associated with an increased mortality risk compared with stage IIIA and stage IIIB(A&B). In the PFS group, the outcome of FIGO 2018 stage IIIC/C1 was similar to stage IIIA (HR 0.66, 95% CI 0.27-1.64, P = 0.371; I2  = 65.6%), but better than stage IIIB(A&B) (HR 0.75, 95% CI 0.68-0.83, P < 0.001; I2  = 0.0%). The FIGO 2018 stage IIIC2 has similar PFS outcomes to stage IIIA and stage IIIB(A&B).Our findings demonstrate that survival outcomes of stage IIIC are no worse than those of stage IIIA and stage IIIB in the 2018 FIGO cervical cancer staging system. In cervical cancer, FIGO 2018 stage IIIC1 has significantly better OS outcomes than stage IIIA and stage IIIB.© 2023 International Federation of Gynecology and Obstetrics.